AA
KYMR icon

AlphaCentric Advisors’s Kymera Therapeutics KYMR Stock Holding History

AlphaCentric Advisors’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$445K Buy
5,342
+307
+6% +$24.3K 0.44% 81
2025
Q4 		$392K Buy
+5,035
New +$340K 0.39% 86

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

AlphaCentric Advisors's KYMR Position: Q1 2026 in Review

AlphaCentric Advisors increased its Kymera Therapeutics (KYMR) stake by 6.1% in Q1 2026, buying an estimated $24.3K and bringing the position to 5,342 shares worth $445K. The position accounts for 0.44% of the portfolio, ranked #81.

AlphaCentric Advisors first reported a position in KYMR in Q4 2025 and has held it in 2 quarters since. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • AlphaCentric Advisors held 5,342 shares of Kymera Therapeutics worth $445K as of Q1 2026.
  • AlphaCentric Advisors bought 307 Kymera Therapeutics shares in Q1 2026, an estimated $24.3K.
  • Kymera Therapeutics made up 0.44% of AlphaCentric Advisors's portfolio in Q1 2026, its #81 holding.
  • AlphaCentric Advisors first reported a position in Kymera Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on AlphaCentric Advisors's 13F filing for Q1 2026, filed 7 May 2026.